Trials / Not Yet Recruiting
Not Yet RecruitingNCT06740539
Atrial Fibrillation with Heart Failure with Preserved Ejection Fraction: Treatment Strategies-Catheter Ablation Vs. Anti-Atrial Arrhythmia Drugs
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 304 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of whether catheter ablation improves the prognosis (all-cause mortality and/or the composite endpoint of MACE) and reduces the recurrence rate of atrial fibrillation (AF) in patients with AF and heart failure with preserved ejection fraction (HFpEF), compared to anti-atrial arrhythmia drugs (AAD). This trial was randomly divided into two groups: the anti-AAD drug group and the catheter ablation group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Catheter ablation of atrial fibrillation | Catheter ablation of atrial fibrillation |
Timeline
- Start date
- 2024-12-16
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2024-12-18
- Last updated
- 2024-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06740539. Inclusion in this directory is not an endorsement.